The first fixed-dose subcutaneous injection of Pfizer's non-factor innovative therapy for hemophilia, Vyondys, has been approved in China.

Pfizer announced that the world's first non-factor innovative drug, Turoctocog alfa pegol, which only requires a fixed dose subcutaneous injection once a week, has been officially approved for marketing by the China National Medical Products Administration. It is suitable for routine prophylactic treatment of severe hemophilia A without factor VIII inhibitors or severe hemophilia B without factor IX inhibitors in children and adults aged 12 and above, with a body weight 35kg, to prevent bleeding or reduce the frequency of bleeding episodes.